Polyurethane membrane with porous surface for controlled drug release in drug eluting stent by unknown
Seo and Na Biomaterials Research 2014, 18:15
http://www.biomaterialsres.com/content/18/1/15RESEARCH ARTICLE Open AccessPolyurethane membrane with porous surface for
controlled drug release in drug eluting stent
Eun Ha Seo and Kun Na*Abstract
Background: Membrane covered drug eluting stents (DES) were prepared to prevent tumor ingrowth and to
control drug release. Polyurethane (PU) is commonly used for DES coating material because of high tensile
strength. The release of paclitaxel (PTX) may increase from porous PU membrane.
Results: Polyethylene glycol (PEG) was incorporated into PU membranes to form porous structure and control the
release of hydrophobic anti-cancer drug such as PTX. The bare metal stents were coated with PEG incorporated PU
and then, PEG was washed out to form porous structure. The crystallization of PTX was inhibited in porous PU
membranes and the release of PTX from porous PU membranes was approximately 8.6% more extended over
19 days.
Conclusions: The enhanced release of PTX from porous PU membranes may increase the patency for the DES
covering materials.
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Most cancers of extrahepatic bile ducts cause biliary ob-
struction [1]. The insertion of a bare metal stent is a
widely used technique for patients with this malignancy,
because this technique prolongs survival, shortens hos-
pital stay, and improves quality of life [2]. However,
these stents also have disadvantages of occlusion over
time because of tumor ingrowth or overgrowth [3], and
mucosal hyperplasia as a consequence of chronic irrita-
tion. Moreover, bare metal stents merely promote biliary
drainage and have no antitumor effect [4].
Alternatively the local drug delivery system via a stent
that is covered with an antitumor-drug-releasing mem-
brane makes it possible to treat a target tissue without
adverse systemic effects [5]. The bare metal stent that is
covered with paclitaxel (PTX) incorporated membrane
that has an antineoplastic effect has been developed [6].
Previously, a polyurethane (PU) membrane was prepared
for potential applications to stent-based drug delivery
and the local treatment of malignant tumors around
non-vascular stents [7]. The PU membrane generally has
a high tensile strength that is physically useful as a* Correspondence: kna6997@catholic.ac.kr
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unless otherwise stated.covering material for gastrointestinal stents that should
be compressed inside an introducer tube with a mini-
mum volume during the delivery to the obstructed
lumen [8]. Based on the upper reasons, the PU mem-
brane was developed and applied using a dip coating
method [9] as part of a PTX-loaded controlled-release
membrane for drug-eluting non-vascular stents.
However, the release of PTX was inversely proportional
to the PTX loading. This type of the smaller drug release
rate with the higher drug loading was reported by S. G.
Kang group [10] investigated the percentage of PTX re-
leased from PU membrane decreased with the increase in
PTX loading. They reported this inverse-relationship of
cumulative release % with drug loading is expected, since
the amount of drug released from the PU membranes was
virtually independent of the drug loading.
Polyethylene glycol (PEG) are commonly incorporated
as a pore forming agent to enhance the release of hydro-
phobic drugs [11]. PEG was incorporated in PU and
washed out from PU membranes to form porous struc-
ture [12,13]. The increased surface area of porous struc-
ture can facilitate a hydrophobic drug release rate even
though higher drug loading [14]. Therefore, we assumed
that the porous PU membrane using PEG has possibilitytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,












PEG 0% 0.0 500.0 10.0 16.0 (±3.6)
PEG 10% 61.1 500.0 10.0 12.7 (±1.2)
PEG 20% 137.5 500.0 10.0 11.3 (±0.1)
PEG 30% 235.7 500.0 10.0 14.0 (±0.1)
aMeasured by micro-meter caliper.
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(DES).
In this study, the influence of porous structure in the
PTX incorporated PU membrane was investigated. Also,
the surface morphology and pore size were determined
by SEM and drug release behavior was confirmed.
Methods
Materials
Polyurethane (PU, Pellethane 2363-80AE, Lubrizol) and
bare metal stents were supplied by Teawoong medical co.
Ltd. (Kimpo-si, South Korea). Polyethylene glycol (PEG,
average Mn 2,050), tert-butyl methyl ether (tBME), tween
20 was purchased from Sigma Aldrich (St.Louis, MO,
USA) and tetrahydrofuran (THF) was purchased from
Junsei chemical (Tokyo, Japan). Paclitaxel (PTX) was pur-
chased from Samyang biopharmaceuticals (Seoul, South
Korea). All of the other chemicals and solvents were ana-
lytical grade.
Preparation of PU membranes and PU coated bare metal
stents
The predetermined amounts of PEG (0, 10, 20, 30%, w/w)
and 500 mg of PU (5%, w/v) were dissolved in 10 ml of
THF (Table 1). The PU solutions containing various
amount of PEG were vigorously stirred to obtain homo
genous solution for 24 hours. PU membranes were fabri-
cated using the dip coating technique on a polytetra-
fluoroethylene (Teflon) bar (Ø: 10 mm). The teflon bars
dipped into PU solutions containing PEG of 0, 10, 20Figure 1 Surface and cross-sectioned scanning electron micrographsand 30% (w/w) and withdrawn, respectively. The PEG in-
corporated PU membranes were dried at room temperature
for 24 hours [15] and then washed in distilled water for fur-
ther 24 hours to wash out PEG and form porous structure.
The porous PU membrane covered bare metal stents were
coated by same methods via coating and washing process
of PEG on bare metal stents. Finally, PU membranes and
PU membrane covered stents were cut and used for further
studies.
Characterization of PU membranes
Thickness of PU membranes was measured by micro-
meter caliper (Mitutoyo, Japan). Surface and cross-sec
tioned morphology of PU membranes and PU coated
bare metal stents were observe with field emission-
scanning electron microscopy (FE-SEM, Hitachi S-4800,
Tokyo, Japan). The membranes and stents were sliced
into small pieces (1 cm × 1 cm), mounted on carbon
tape, sputter coated with platinum using an ion coater
(10 mA, 45 sec), and then observed at an accelerating
voltage of 10 kV.
In vitro PTX release test
PTX (50 mg) was added into 10 mL of PU solution con-
taining various amount of PEG. PTX loaded porous PU
membrane was fabricated by above-mentioned method. To
investigate drug release profile, approximately 0.46 mg/
cm2 of PTX incorporated porous and non-porous PU
membranes were fabricated. The membranes were placed
into 15 mL conical tubes, and 10 mL of 0.1% of tween 20
containing 0.01 M phosphate-buffered saline solution
(PBST) was added (n = 3). Release test was performed in
shaking water bath at 37°C and 50 rpm for 19 days. The
PBST in each tube was collected and replaced at specified
times. The released PTX was extracted into tBME. The
tBME was completely evaporated at room temperature for
overnight and re-dissolved in 200 μL of HPLC grade
methanol (Honeywell-Burdick and Jackson). The released
PTX was quantified by high performance liquid chroma-
tography (HPLC) equipped with ultraviolet (UV) detectorof PU membranes before and after washing process.
Figure 2 Scanning electron micrographs of paclitaxel (PTX)
incorporated PU membranes before and after washing process.
Figure 3 Determination of pore size of PU membranes after
washing process. (A) Scanning electron micrographs and (B) pore
size distribution of PU membranes depending on PEG concentration.
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methanol as the mobile phase at room temperature [16].
The column was C18 reverse phase column (Thermo Sci-
entific). The HPLC was calibrated with PTX standard solu-
tions of 1 to 100 μg/mL (correlation coefficient R2 = 0.998).
Results and discussion
Characterization of PU membranes
The thickness of the PU membranes had a few difference
but not significantly affected. PEG 0% PU membrane wasFigure 4 The porous PU membranes were applied to bare
metal stents. (A) The digital image and (B) scanning electron
micrographs of PU coated bare metal stents depending on
PEG concentration.
Table 2 PTX-incorporated PU membranes
Membrane type (w/w%) PTX amounts (mg/cm2)
PEG 0% 0.465 (±0.002)
PEG 10% 0.467 (±0.002)
PEG 20% 0.466 (±0.001)
PEG 30% 0.461 (±0.009)
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11.3 ± 0.1 μm and PEG 30% was 14.0 ± 0.1 μm (Table 1).
SEM observation of the PU membranes demonstrated that
the surface and cross-sectioned was porous structure after
PEG incorporating and washing out from PU membranes
(Figure 1). On microscopic examination of the PTX-
incorporated PU membranes with SEM, we could find ag-
gregated and cracked PTX for PEG 0% PU membrane, but
PTX crystallization wasn’t found on the surface of PEG
10% PU membrane which was a porous membrane
(Figure 2). This PTX crystal and cracks allow limited
release of PTX from membranes because of rate-limiting
detachment of the drug from the PTX-incorporated mem-
branes [17]. In other words, the porous PU membrane can
inhibit PTX crystallization and then, PTX release was ex-
pected to enhance.
PU membrane stent cover depending on PEG
concentration
Each membrane type has uniform pore size (Figure 3A)
and measurement of pore size was increased proportion-
ally to PEG concentration (Figure 3B). PEG was incorpo-
rated into PU membrane and washed out in water. The
membranes increase in the equilibrium water uptake.
This was attributed to the formation of a porous struc-
ture in PU membranes. It was also evidenced by the ob-
served increase in the diffusion coefficients. Generally,
as diffusion is known to play a major role in the control
of drug release [18,19].
According to our stent design, the porous PU mem-
brane was designated as coating membrane on bare metal
stent. The PU membrane was formed between metalFigure 5 Accumulative PTX release profile depending on
PEG concentration.(Figure 4A). The porous structure of PU membranes coat-
ing on bare metal stents can be described like that PU
membranes itself, as shown in Figure 4B.
In vitro PTX release test
The PTX release behaviors of PU membranes under
simulated physiological conditions (PBST, pH 7.4, 37°C)
were investigated and compared (Figure 5). Overall PTX
loading was approximately 0.461–0.467 mg/cm2. PTX
loading amounts was 0.465 mg/cm2 in PEG 0% PU mem-
brane, 0.467 mg/cm2 in PEG 10%, 0.466 mg/cm2 in PEG
20% and 0.461 mg/cm2 in PEG 30% (Table 2). The re-
leased PTX, which was calculated based on the % released
for 19 days, was 34.0% (released amount: 0.158 mg/cm2)
from PEG 0% PU membrane, 38.9% (0.182 mg/cm2) from
PEG 10%, 42.6% (0.198 mg/cm2) from PEG 20%, and
40.0% (0.185 mg/cm2) from PEG 30% (Figure 5). PEG 20%
membrane showed the greatest release of PTX. Because
PEG 30% membranes has too much larger pore size than
PEG 10 and 20% membranes so, surface area of PEG 30%
membranes is smaller than PEG 20% membranes [20].
As a result of the release properties associated with
porous PU membranes, PTX crystallization was pro-
tected and increased surface area could more release
from PU membranes.
Conclusions
In this study, we investigated the effect of porous PU
membrane as a bare metal stent coating material. The
porous structure was formed by washing out of PEG
from PU membranes. The release of PTX from porous
PU membranes was increased for 19 days. This porous
PU membrane could inhibit PTX crystallization and in-
crease drug release because porous structure had larger
surface area. The enhanced release of drug from porous
PU membranes increases the potential usefulness of a
bare metal stent cover to limited drug release of hydro-
phobic anti-cancer drug, PTX.
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